BioSig Technologies Reaches Catalyst Outlined By CEO Greg Cash

In an interview with Investing News on March 8, 2016 BioSig Technologies (OTCQB:BSGM) CEO, Greg Cash, spoke of near-term catalysts, including the presentation of its pre-clinical data by the Mayo Clinic.
On March 23, 2016 BioSig Technologies announced the establishment of an advanced research program with Dr. Samuel Asirvatham at the Mayo Clinic in Rochester, Minnesota.
Beyond that, the company is looking to submit its 510(k) to the US Food and Drug Administration (FDA) for clearance to market in 2016.
BioSig Technologies President and CEO, Greg Cash, stated:

We are extremely pleased to continue our relationship with Dr. Asirvatham and his colleagues at the Mayo Clinic. The previous studies confirmed the potential of PURE EP to improve the clarity of cardiac signals while minimizing electrical noise in the cardiac electrophysiology laboratory.

Connect with BioSig Technologies (OTCQB:BSGM) to receive an Investor Presentation.